Asciminib
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 345 publications
Revisiting Asciminib Resistance: From Binding Affinity to Allosteric Disruption in BCR::ABL1 Leukemias.
Journal: Turkish journal of haematology : official journal of Turkish Society of Haematology
Published: September 08, 2026
Nilotinib in chronic myeloid leukemia: clinical value, real-world challenges, and the potential of nilotinib tablets to improve therapeutic outcomes.
Journal: Expert review of hematology
Published: August 12, 2026
Connecting asciminib tolerability to long-term treatment persistence. Comment on: "Favorable tolerability of asciminib versus ATP-competitive tyrosine kinase inhibitors in the ASC4FIRST study of newly diagnosed patients with chronic-phase chronic myeloid leukemia".
Journal: Haematologica
Published: July 15, 2026
Allosteric kinase inhibition in hematological malignancies: from asciminib to emerging regulatory sites.
Journal: Biochemical pharmacology
Published: July 10, 2026
Ponatinib plus asciminib in myeloid blast-phase CML harboring a phased BCR::ABL1 Y253H/T315I compound mutation: a case report.
Journal: Frontiers in oncology
Published: July 05, 2026
Independent PML::RARA-positive acute promyelocytic leukemia arising during BCR::ABL1-positive chronic myeloid leukemia.
Journal: Journal of clinical and experimental hematopathology : JCEH
Published: June 28, 2026
Matching-adjusted indirect comparison between asciminib and flumatinib as first-line treatment for chronic myeloid leukemia in China.
Journal: Translational cancer research
Published: June 23, 2026
Financial Impact of Treatment Choice in Chronic Myeloid Leukemia: A Comparison of Later Generation TKIs versus Imatinib from Patient and Payer Perspectives.
Journal: ClinicoEconomics and outcomes research : CEOR
Published: May 30, 2026
A novel hyperactive BCR::ABL1 e6a3 variant confers resistance to combined asciminib plus ponatinib therapy.
Journal: medRxiv : the preprint server for health sciences
Published: May 04, 2026
Pharmacokinetics of asciminib in a patient with chronic myeloid leukemia undergoing maintenance hemodialysis.
Journal: Cancer chemotherapy and pharmacology
Published: May 04, 2026
Importance of five membered heterocyclic compounds in treatment of chronic myeloid leukemia by targeting various pathways.
Journal: Future medicinal chemistry
Published: April 21, 2026
Last Updated: 09/26/2026